Filing Flows › Health Care › Accustem Sciences (ACUT)
Accustem Sciences (ACUT) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Accustem Sciences (ACUT) Q2 2026 earnings results →
Q2 2026 257¢ of every $1 of revenue lost · operating margin -256.7%
Accustem Sciences made $98K in Q2 2026. Operating margin -256.7%, net loss $253K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $98K in Q2 2026.
Operating costs exceeded revenue by $253K, an operating margin of -256.7%. The quarter ended with a net loss of $253K.
Operating cash flow was −$249K. Non-cash charges added back $7K of share-based compensation.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $98K | — | -256.7% | −$253K | −$249K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Accustem Sciences
We are a clinical stage diagnostics company dedicated to improving quality of life and outcomes for the millions of people worldwide who are diagnosed with cancer each year. Our plan is to develop and commercialize a suite of novel genomic tests that support decision making along the entire continuum of oncology care. Our focus will be the launch of our proprietary genomic tests, MSC (MicroRNA Signature Classifier) for patients with lung nodules and StemPrintER for patients with early stage breast cancer. We estimate this market opportunity represents more than $6.3 billion in annual revenue in the US, where we will focus our initial commercialization efforts.
In its own words, from its 10-K, filed Apr 14, 2026.
Accustem Sciences against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: -256.7% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ACUT Accustem Sciences | Q2 2026 | $98K | — | -256.7% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Accustem Sciences 10-Q on SEC EDGAR · CIK 1850767 · Pharmaceutical Preparations
More on ACUT
History
Every quarter: Q2 2026 results